NeuraLight develops a software system that uses ordinary webcams or smartphones and modern image analysis to extract sub-pixel ocular signals linked to cognitive load and neurological disease. The core product claims accuracy comparable to professional gaze trackers that cost tens of thousands of dollars by deriving micro-parameters from the eye. The company positions its measurements as an objective metric to improve diagnosis and tracking and to tag patients in clinical trials, increasing confidence in study data without making regulated diagnostic claims. NeuraLight has tested hundreds of healthy volunteers as a control group and is preparing studies to create an agent to detect ALS; trials and partnerships are also underway for Parkinson’s, MS and Alzheimer’s. The team envisions passive, frequent home or telehealth monitoring (including via standard video calls), but clinical deployment will require more tests and FDA approval. NeuraLight is based in Austin and Tel Aviv and intends to use new funding to expand its team, infrastructure and product. NeuraLight has built a platform that automatically extracts microscopic ocular metrics from augmented video to serve as digital endpoints for neurological disorders. The company’s technology removes light and movement artifacts from standard smartphone or webcam video and derives precise eye‑movement measurements. NeuraLight plans to sell these digital endpoints to pharmaceutical companies to accelerate clinical trials and improve drug development for Parkinson’s, Alzheimer’s, MS and other neurodegenerative diseases. The company emerged from stealth with $5.5 million in seed funding to advance its platform and partnerships with pharma. NeuraLight aims to assemble a large, de‑identified oculometric database and apply AI to gain insights from thousands of patients. The team is dual‑headquartered in Austin and Tel Aviv and has recruited talent from research, pharma, Google, Chorus.ai and Viz.ai; the founders have filed a provisional patent and report early measurement work underway in Israel.

Total raised

$31M

Funding rounds

2

Latest round

Series A

Latest activity

May 2022